Ab Science Sa

AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients

AB Science provides an update on its clinical development program.

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors